BridgeBio Pharma BBIO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $579.96M+15.5% | $502.08M+41.9% | $353.78M+50.0% | $235.81M+85.1% | $127.42M-42.6% | ||
| $28.26M+34.8% | $20.96M+40.3% | $14.94M+66.5% | $8.97M+51.6% | $5.92M+52.6% | ||
| $551.7M+14.7% | $481.11M+42.0% | $338.84M+49.4% | $226.84M+86.7% | $121.5M-44.3% | ||
| 95.1%-0.7pp | 95.8%0.0pp | 95.8%-0.4pp | 96.2%+0.8pp | 95.4%-2.9pp | ||
| $467.16M+3.4% | $451.95M-3.0% | $465.89M-1.6% | $473.46M-0.7% | $476.92M-5.8% | ||
| $588.76M+10.8% | $531.23M+13.5% | $467.92M+17.2% | $399.12M+21.1% | $329.49M+14.0% | ||
| $1.1B+7.7% | $1.03B+6.4% | $963.66M+8.0% | $892.24M+8.1% | $825.1M+1.3% | ||
| -$525M-0.3% | -$523.41M+14.2% | -$609.88M+7.1% | -$656.43M+5.9% | -$697.69M-17.7% | ||
| -90.5%+13.7pp | -104.2%+68.1pp | -172.4%+106pp | -278.4%+269pp | -547.6%-280pp | ||
| $73.95M-6.5% | $79.13M-11.1% | $89.02M-11.3% | $100.34M+17.2% | $85.64M-5.9% | ||
| $20.72M+4.3% | $19.85M-1.7% | $20.21M+17.0% | $17.26M-7.0% | $18.56M+7.6% | ||
| -$204.46M+2.2% | -$209.09M— | —— | —— | —— | ||
| -$75.34M-3.8% | -$72.61M-6.3% | -$68.27M-15.7% | -$59M-26.2% | -$46.74M-49.9% | ||
| $0+100% | -$21.16M0.0% | -$21.16M0.0% | -$21.16M0.0% | -$21.16M+20.4% | ||
| -$729.89M+0.4% | -$732.94M+9.0% | -$805.69M-2.6% | -$785.01M-16.0% | -$676.8M-24.6% | ||
| -125.9%+20.1pp | -146%+81.8pp | -227.7%+105pp | -332.9%+198pp | -531.2%-286pp | ||
| -$3.73+1.1% | -$3.77+10.2% | -$4.20-2.2% | -$4.11-15.8% | -$3.55-23.7% | ||
| -$3.73+1.1% | -$3.77+10.2% | -$4.20-2.2% | -$4.11-15.8% | -$3.55-23.7% | ||
| 768.7M+0.6% | 764M+0.7% | 758.6M+0.4% | 755.2M+0.4% | 752.3M+1.5% | ||
| 768.7M+0.6% | 764M+0.7% | 758.6M+0.4% | 755.2M+0.4% | 752.3M+1.5% | ||
| $140.99M+12.7% | $125.14M+32.1% | $94.76M+62.4% | $58.35M— | —— | ||
| $39.08M-9.2% | $43.06M+31.0% | $32.86M+80.6% | $18.2M+65.2% | $11.02M-10.2% | ||
| $20.78M-2.7% | $21.35M+43.2% | $14.91M+39.5% | $10.69M-16.3% | $12.78M-18.1% | ||
| $579.96M+15.5% | $502.08M+41.9% | $353.78M+50.0% | $235.81M+85.1% | $127.42M-42.6% | ||
| -$525M-0.3% | -$523.41M+14.2% | -$609.88M+7.1% | -$656.43M+5.9% | -$697.69M-17.7% | ||
| -$519.66M-0.3% | -$517.98M+14.3% | -$604.51M+7.1% | -$650.92M+5.9% | -$691.93M-17.9% | ||
| -$519.66M-0.3% | -$517.98M+14.3% | -$604.51M+7.1% | -$650.92M+5.9% | -$691.93M-17.9% | ||
| -89.6%+13.6pp | -103.2%+67.7pp | -170.9%+105pp | -276%+267pp | -543%-279pp | ||
| -$525M-0.3% | -$523.41M+14.2% | -$609.88M+7.1% | -$656.43M+5.9% | -$697.69M-17.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BridgeBio Pharma's revenue?
- BridgeBio Pharma (BBIO) generated $580.0M in revenue over the trailing twelve months, up 355.2% year over year.
- Is BridgeBio Pharma profitable?
- BridgeBio Pharma is not currently profitable: it reported a net loss of $729.9M over the trailing twelve months, a -125.9% net margin.
- What are BridgeBio Pharma's profit margins?
- Gross margin is 95.1% and operating margin is -90.5%, with a -125.9% net margin.
- What is BridgeBio Pharma's earnings per share?
- BridgeBio Pharma's diluted EPS over the trailing twelve months is $-3.73.
- Where does BridgeBio Pharma's income statement data come from?
- Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
